Actively Recruiting

Phase 2
Age: 8Years - 17Years
All Genders
NCT05866536

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Led by Massachusetts General Hospital · Updated on 2025-12-10

100

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect in new onset pediatric Type 1 diabetes.

CONDITIONS

Official Title

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

Who Can Participate

Age: 8Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with Type 1 diabetes more than 3 months but less than 12 months before randomization
  • Male or female aged 8 to under 18 years at screening and under 18 at randomization
  • HIV antibody negative at screening
  • Negative pregnancy test if female at screening
  • Negative for tuberculosis with a QuantiFERON-TB test before randomization
  • Provided informed consent and child assent as appropriate
  • Diagnosed with Type 1 diabetes by WHO/ADA glucose criteria prior to enrollment
  • Presence of at least one diabetes-related autoantibody before randomization
  • Treated with insulin before screening
  • Able and willing to follow the study protocol including self-measuring plasma glucose
Not Eligible

You will not qualify if you...

  • Clinically significant abnormal blood counts or chemistries at screening
  • Elevated creatinine above Grade 1 at screening
  • History of chronic infectious diseases like HIV or untreated hepatitis
  • History or positive test for tuberculosis or high mycobacterial exposure
  • Current use of systemic glucocorticoids or likely need for high dose steroids
  • Participation in another clinical trial within 28 days before screening
  • Previous participation in biologic or drug intervention trials for Type 1 Diabetes
  • Other active chronic conditions increasing risk of serious side effects
  • Chronic use of high-dose aspirin or daily NSAIDs
  • Use of chronic antibiotics interfering with BCG
  • History of recurrent ketoacidosis with hospitalizations
  • History of keloid formation
  • Chronic kidney disease or significant diabetes complications
  • Body mass index below 5th or above 95th percentile
  • Blood pressure above 90th percentile for age and sex
  • Fever above 99.8 F or abnormal heart rate at screening
  • History of proliferative diabetic retinopathy
  • History of type 2 diabetes or severe obesity
  • Diabetes onset before age 1
  • Monogenic diabetes or diabetes secondary to cystic fibrosis
  • Lacking diabetes-specific autoantibodies
  • History of severe diabetes complications or non-compliance
  • Conditions affecting red blood cell turnover
  • Pregnancy, breastfeeding, or inadequate contraception if female
  • Living with someone immunosuppressed or at high risk for infections
  • Participation in other BCG or immunotherapy diabetes trials
  • Use or planned use of type 2 diabetes drugs or oral blood sugar medications
  • History of prior BCG vaccination or positive tuberculosis tests
  • Not born in the United States
  • Known hypersensitivity to trial products
  • Planned medication changes affecting glucose metabolism
  • Any condition risking safety or compliance
  • Recent diagnosis of cancer
  • Severe hypoglycemic episodes or unawareness
  • Multiple recent diabetic ketoacidosis hospitalizations
  • Recent treatment with diabetes medications other than insulin
  • History of lupus

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Immunobiology Labs CNY 149

Charlestown, Massachusetts, United States, 02129

Actively Recruiting

Loading map...

Research Team

D

Denise L Faustman, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years | DecenTrialz